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repositionable system with a nitinol stent frame and bovine pericar-
dial leaﬂets, which is increasingly utilized for transcatheter aortic
valve replacement (TAVR) in patients with severe native aortic ste-
nosis at high risk of conventional surgery. In this report, we describe
the procedural and early clinical results from an international multi-
center registry of Portico implantation in patients with degenerated
aortic bioprosthesis (Portico ViV).
METHODS Baseline demographics, procedural and clinical outcomes
were collected on standard case report forms and by the Valve-in-
Valve International Data network from 14 centers across three conti-
nents. Procedural endpoints included implantation success and cor-
onary obstruction. Clinical endpoints included death, myocardial
infarction (MI), stroke, major bleeding at 30 days as deﬁned by Valve
Academic Research consortium II (VARCII).
RESULTS 45 patients undergoing Portico ViV were included in anal-
ysis. The mean age was 79 7 years with STS (mortality) score of 74.
These procedures had mainly utilized peripheral arterial access (93%),
with transesophageal echocardiogram guidance (60%) for treatment
of surgical valve label size 21, >21-<25, and 25mm in 36, 38 and 27%
respectively. Four (9%) of the failed surgical bioprostheses were
stentless. Successful implantation was achieved in 44 (98%) cases
with no malposition events or clinically-evident coronary obstruction.
Post implantation valve area was 1.3 0.4 cm2, mean gradient of 17.1 
7.7 mmHg and moderate aortic insufﬁciency was observed in 3 (7%).
One death (2%) related to ischemic stroke occurred within 30 days.
Major bleeding and vascular complication in 5 (11%) and 1 (2%)
respectively. One patient required permanent pacemaker implanta-
tion (2%).
CONCLUSIONS Results from this international multicenter registry
show that Portico offers a safe and effective treatment of failed sur-
gical bioprosthesis with an added advantage of device retrievability,
resulting in low incidence of malpositioning and coronary obstruc-
tion. Additional studies and comparison with other transcatheter
devices should further determine the hemodynamic and clinical per-
formance of this device for selection of optimal treatment of high risk
patients with failed surgical bioprostheses.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is the
treatment option of choice for high surgical risk patients presenting
with severe symptomatic aortic stenosis. First generation devices were
limited by non-negligible TAVI-related complications including 2
paravalvular leak (PVL) and vascular complications that are predictors
of mortality. As a result, newer devices have been developed to over-
come these limitations. We aimed to compare procedural and clinical
outcomes between contemporary and ﬁrst generation devices.
METHODS A retrospective analysis was conducted of all patients that
underwent transfemoral TAVI between November 2007 and May 2015
at San Raffaele Scientiﬁc Institute, Milan, Italy. Patients treated with
an Edwards Sapien XT (Edwards LifeSciences, CA) or a CoreValve
(Medtronic, CA) were allocated to the ﬁrst-generation group (1G).
Patients treated with an Edwards Sapien 3 (Edwards LifeSciences),
Evolut R (Medtronic), Lotus (Boston Scientiﬁc, MA) or Direct Flow
(Direct Flow Medical, CA) valves were allocated to the second-gen-
eration group (2G).RESULTS 449 patients were included in the 1G, and 179 patients to
the 2G. Patients in the FG were older (83.4 vs. 82.1 years, p¼0.03), of
a higher risk proﬁle (Euroscore 10 vs. 9.5, p¼0.04) with a similar
gender preponderance (female: 61.2% vs. 61.4%, p¼0.79). Peri-pro-
cedurally, there was a lower incidence of major or life-threatening
bleeding complications in the 2G compared to the 1G (8.4% vs. 21.4%,
p<0.001) and 2 PVL (6.1% vs. 17.1%, p¼0.003) with no differences in
the rates of stroke (3.3% vs. 1.8%, p¼0.23) or PPM implantation (11.2%
vs. 12.7%, p¼0.6) respectively. Mortality at 30-days (3.6% vs. 1.4%,
p¼0.77) and at 1-year (11.2% vs. 12.7%, p¼0.81) were similar between
groups.
CONCLUSIONS This single-center retrospective study demonstrates
that newer generation TAVI devices are associated with a reduction
in 2 PVL and major and life-threatening bleeding events when
compared to ﬁrst generation devices. There were no differences in
short-term mortality. Longer-term follow-up are required to deter-
mine if these short-term procedural improvements are translated into
a longer-term outcome beneﬁt.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is
a treatment for patients with aortic stenosis deemed high risk
for aortic valve replacement (AVR). Advancing age independently
predictors mortality after AVR, so that most patients undergoing
TAVI are elderly. This study presents UK trends in activity and
outcomes for TAVI and AVR in patients aged 80 or over in the
“TAVI era”.
METHODS Data for all AVR and TAVI procedures between January-
2006 and December-2012 were sourced from (i) the UK Cardiac Sur-
gery Registry and (ii) the UK-TAVI Registry. Patient demographics, 30-
day mortality, postoperative length of stay (PLOS), 1-year and 5-year
survival were analyzed for four groups: TAVI, AVR, AVRþcoronary
artery bypass graft surgery (CABG), and AVRþother concomitant
surgery.
RESULTS Total aortic valve interventions increased between 2006
and 2012 from 1206 to 2668 (by 121%). Between 2006 and 2012, the
number of isolated AVR procedures increased from 485 to 808 (by
67%), while between 2007 and 2012, TAVI increased from 47 to 798
(by 160%). TAVI patients were older, more likely to be female, in
NYHA class IV, with prior cardiac surgery, renal, pulmonary, and
ventricular dysfunction, extra-cardiac arteriopathy, and neurological
disease than AVR patients (logistic EuroSCORE 23.513.7 vs. 13.69.5,
p<0.001). 30-day mortality was 10.55% (AVRþother), 5.61%
(AVRþCABG), 5.54% (TAVI), and 3.45% (AVR). Mean PLOS (days)
were 17.8 (AVRþother), 14.4 (AVRþCABG), 12.6 (AVR), and 9.1
(TAVI). 1-year survival was 89.6% (AVR), 85.1% (AVRþCABG), 81.9%
(TAVI), and 78.8% (AVRþother surgery). 5-year survival was 64.2%
(AVR), 59.7% (AVRþCABG), 56.5% (AVRþother surgery), and 43.4%
(TAVI).
CONCLUSIONS In 2007, TAVI made up only 3% of all aortic valve
interventions in patients 80 years. This had increased ten-fold to
almost 30% of all aortic valve interventions by 2012. Despite increased
age and risk scores, length of hospital stay was shorter, and 30-day
and 1-year mortality rates were comparable with other aortic valve
interventional groups.
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